Publications by authors named "Cutuli H"
Article Synopsis
- The CheckMate 914 trial investigated the effectiveness of adjuvant nivolumab monotherapy compared to placebo in patients with localized renal cell carcinoma (RCC) at high risk of recurrence after surgery.
- Despite enrolling 825 patients, the results showed that nivolumab did not significantly improve disease-free survival (DFS) compared to placebo.
- Additionally, safety data indicated that adverse events were reported at different rates among the treatment groups, but overall, the trial did not achieve its primary goal of improved DFS for nivolumab.
Article Synopsis
- The evolving oncology treatment landscape shows a need for better administration options that enhance patient experiences and healthcare efficiency.
- A phase III trial (CheckMate 67T) compared subcutaneous nivolumab to intravenous nivolumab in patients with advanced clear cell renal cell carcinoma, focusing on pharmacokinetics and objective response rates.
- Results indicated that subcutaneous nivolumab was noninferior to the intravenous form, showing similar efficacy and safety profiles, with no new safety concerns emerging.
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Clin Genitourin Cancer
October 2024
Article Synopsis
- The study investigates the prevalence of FGFR mutations and fusions in Latino patients with metastatic urothelial carcinoma (mUC), finding these alterations in 17.9% of the analyzed population.
- Despite the presence of FGFR alterations, there was no significant difference in overall survival and time to treatment failure compared to patients without these mutations.
- The research also validates Bellmunt's prognostic model for predicting overall survival in this specific cohort of patients.
Article Synopsis
- * Methods: Researchers analyzed data from 94 patients treated at 29 institutions, assessing various factors like type of therapy, timing of recurrence, and patient risk categories, while also monitoring treatment-related side effects.
- * Key Findings: The study revealed an 18-month PFS rate of 45% and overall survival (OS) rate of 85%, with common treatment-related side effects including skin toxicity and fatigue; it did have limitations due to patient selection.
Article Synopsis
- - The ARON-2 study investigated the real-world effectiveness of pembrolizumab, an immune checkpoint inhibitor, in patients with advanced urothelial carcinoma who had progression after platinum-based chemotherapy, utilizing data from 836 patients across 88 institutions in 23 countries.
- - Results showed median overall survival (OS) of 10.5 months and overall response rate (ORR) of 31%; those who progressed after initial chemotherapy (cohort A) had lower OS (9.1 months) compared to those who recurred within a year post-chemotherapy (cohort B) with 14.6 months OS.
- - Multivariate analysis identified several prognostic factors affecting OS and progression-free survival (PFS),
Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations are commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMIBC and select FGFR3/2 alterations following recurrence after BCG treatment.
View Article and Find Full Text PDFBackground: Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable safety in patients with platinum-refractory urothelial carcinoma (UC).
Objective: To evaluate pembrolizumab plus either lenvatinib or placebo as first-line therapy for advanced UC in the phase 3 LEAP-011 study.
Design, Setting, And Participants: Patients with advanced UC who were ineligible for cisplatin-based therapy or any platinum-based chemotherapy were enrolled.
Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab.
Methods: We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries.
Background: Renal cell carcinoma (RCC) represents 1% of all cancers and its brain metastases amount to 8.1% of all metastatic tumors. Late brain metastases are defined as tumors that appear 10 years after diagnosis of the primary lesion.
View Article and Find Full Text PDFArticle Synopsis
- Radiation therapy is an effective treatment for testicular seminoma after orchiectomy, but information on relapses post-treatment is limited.
- A study of 61 patients revealed high survival rates: 90% disease-free and 98% overall survival at 5 years, with most relapses occurring more than 15 months after radiation.
- The majority of relapses were managed successfully with cisplatin-based chemotherapy, leading to strong outcomes and highlighting the need for awareness of potential late relapses.
Objectives: Describe the time elapsed from the diagnosis to treatment with chemotherapy for patients with breast and lung cancer at public and private hospitals in Buenos Aires.
Design: Retrospective cohort study.
Setting: Three public and three private academic hospitals in Buenos Aires.
Teratomas are malign germ cell tumors composed of two or more tissue layers. When there is specific organ differentiation they are called mature teratoma. They rarely grow aggressively.
View Article and Find Full Text PDF